<?xml version="1.0" encoding="UTF-8"?>
<p>The study enrolled 148 patients between March 2013 and August 2014 at 27 study sites in six countries (Australia, Georgia, Hungary, Israel, Poland, and the USA); all enrolled patients were included in the safety population (Fig. 
 <xref rid="cam41388-fig-0001" ref-type="fig">1</xref>). The evaluable population comprised 147 patients who received at least one treatment with TC chemotherapy and at least one dose of either pegfilgrastim (
 <italic>n</italic> = 36) or Rolontis (
 <italic>n</italic> = 39 at 45 
 <italic>μ</italic>g/kg, 
 <italic>n</italic> = 36 at 135 
 <italic>μ</italic>g/kg and 
 <italic>n</italic> = 36 at 270 
 <italic>μ</italic>g/kg) (Table 
 <xref rid="cam41388-tbl-0001" ref-type="table-wrap">1</xref>).
</p>
